BIOMARK RES 润色咨询

Biomarker Research

出版年份：暂无数据 年文章数：255 投稿命中率： 开通期刊会员，数据随心看

出版周期：C 自引率：暂无数据 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2127118, encodeId=dd57212e11861, content=生信+实验收吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=261c5473647, createdName=ms1000000858912769, createdTime=Wed Apr 19 20:46:55 CST 2023, time=2023-04-19, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2263172, encodeId=b33722631e26f, content=审稿速度:1.0<br>偏重的研究方向：肿瘤;标志物<br>经验分享：with editor两周peer review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05805608050, createdName=ms6000001390648073, createdTime=Fri May 02 14:25:31 CST 2025, time=2025-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2241152, encodeId=4c612241152c6, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤;遗传<br>经验分享：投稿10天了，在With editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18286518503, createdName=ms4000000726733331, createdTime=Fri Dec 06 22:45:15 CST 2024, time=2024-12-06, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2253089, encodeId=be662253089a4, content=投稿命中率:95.0<br>经验分享：垃圾杂志，投了半个月还在with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80862476544, createdName=1244bb2bm58(暂无昵称), createdTime=Sat Feb 22 14:14:37 CST 2025, time=2025-02-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2259792, encodeId=773b2259e9254, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：肿瘤<br>经验分享：难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51945464829, createdName=ms1000001718056820, createdTime=Wed Apr 09 20:17:18 CST 2025, time=2025-04-09, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2252640, encodeId=76eb225264051, content=偏重的研究方向：分子生物学;肿瘤<br>经验分享：综述。最开始投的是Journal of Hematology & Oncology，然后推荐转投。下面是时间表，供大家参考。 Submission received-04 Nov 2024 Ready for editorial assignment-05 Nov 2024 Editor assigned-05 Nov 2024 First reviewer(s) invited-18 Nov 2024 Revision requested-16 Dec 2024 Revision received-25 Jan 2025 Revision requested-02 Feb 2025 Submission accepted-11 Feb 2025, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24889227969, createdName=ms4000000145088894, createdTime=Wed Feb 19 14:17:01 CST 2025, time=2025-02-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2252639, encodeId=853a225263940, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：分子生物学;肿瘤<br>经验分享：综述。最开始投的是Journal of Hematology & Oncology，然后推荐转投。下面是时间表，供大家参考。<br>Submission received-04 Nov 2024<br>Ready for editorial assignment-05 Nov 2024<br>Editor assigned-05 Nov 2024<br>First reviewer(s) invited-18 Nov 2024<br>Revision requested-16 Dec 2024<br>Revision received-25 Jan 2025<br>Revision requested-02 Feb 2025<br>Submission accepted-11 Feb 2025<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24889227969, createdName=ms4000000145088894, createdTime=Wed Feb 19 14:09:36 CST 2025, time=2025-02-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2245674, encodeId=83f622456e45e, content=还没投，来看看大家的意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=9cc95195872, createdName=14728102m68暂无昵称, createdTime=Tue Dec 31 09:09:15 CST 2024, time=2024-12-31, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2238194, encodeId=2fbb223819434, content=审稿速度:12.0 | 投稿命中率:5.0<br>经验分享：lj杂志，两个审稿人都同意接收的前提下编辑没有任何理由给拒了，半年白费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66255430118, createdName=ms2000001500604715, createdTime=Thu Nov 21 16:15:16 CST 2024, time=2024-11-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2191999, encodeId=591c2191999ef, content=The editors' decision can take several weeks as they may consult peer reviewers. 是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=780c5321661, createdName=148ad189m02(暂无昵称), createdTime=Fri Mar 08 09:34:46 CST 2024, time=2024-03-08, status=1, ipAttribution=北京)]
    2023-04-19 ms1000000858912769 来自湖北省

    生信+实验收吗？

    3

    展开3条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2127118, encodeId=dd57212e11861, content=生信+实验收吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=261c5473647, createdName=ms1000000858912769, createdTime=Wed Apr 19 20:46:55 CST 2023, time=2023-04-19, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2263172, encodeId=b33722631e26f, content=审稿速度:1.0<br>偏重的研究方向：肿瘤;标志物<br>经验分享：with editor两周peer review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05805608050, createdName=ms6000001390648073, createdTime=Fri May 02 14:25:31 CST 2025, time=2025-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2241152, encodeId=4c612241152c6, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤;遗传<br>经验分享：投稿10天了，在With editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18286518503, createdName=ms4000000726733331, createdTime=Fri Dec 06 22:45:15 CST 2024, time=2024-12-06, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2253089, encodeId=be662253089a4, content=投稿命中率:95.0<br>经验分享：垃圾杂志，投了半个月还在with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80862476544, createdName=1244bb2bm58(暂无昵称), createdTime=Sat Feb 22 14:14:37 CST 2025, time=2025-02-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2259792, encodeId=773b2259e9254, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：肿瘤<br>经验分享：难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51945464829, createdName=ms1000001718056820, createdTime=Wed Apr 09 20:17:18 CST 2025, time=2025-04-09, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2252640, encodeId=76eb225264051, content=偏重的研究方向：分子生物学;肿瘤<br>经验分享：综述。最开始投的是Journal of Hematology & Oncology，然后推荐转投。下面是时间表，供大家参考。 Submission received-04 Nov 2024 Ready for editorial assignment-05 Nov 2024 Editor assigned-05 Nov 2024 First reviewer(s) invited-18 Nov 2024 Revision requested-16 Dec 2024 Revision received-25 Jan 2025 Revision requested-02 Feb 2025 Submission accepted-11 Feb 2025, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24889227969, createdName=ms4000000145088894, createdTime=Wed Feb 19 14:17:01 CST 2025, time=2025-02-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2252639, encodeId=853a225263940, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：分子生物学;肿瘤<br>经验分享：综述。最开始投的是Journal of Hematology & Oncology，然后推荐转投。下面是时间表，供大家参考。<br>Submission received-04 Nov 2024<br>Ready for editorial assignment-05 Nov 2024<br>Editor assigned-05 Nov 2024<br>First reviewer(s) invited-18 Nov 2024<br>Revision requested-16 Dec 2024<br>Revision received-25 Jan 2025<br>Revision requested-02 Feb 2025<br>Submission accepted-11 Feb 2025<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24889227969, createdName=ms4000000145088894, createdTime=Wed Feb 19 14:09:36 CST 2025, time=2025-02-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2245674, encodeId=83f622456e45e, content=还没投，来看看大家的意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=9cc95195872, createdName=14728102m68暂无昵称, createdTime=Tue Dec 31 09:09:15 CST 2024, time=2024-12-31, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2238194, encodeId=2fbb223819434, content=审稿速度:12.0 | 投稿命中率:5.0<br>经验分享：lj杂志，两个审稿人都同意接收的前提下编辑没有任何理由给拒了，半年白费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66255430118, createdName=ms2000001500604715, createdTime=Thu Nov 21 16:15:16 CST 2024, time=2024-11-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2191999, encodeId=591c2191999ef, content=The editors' decision can take several weeks as they may consult peer reviewers. 是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=780c5321661, createdName=148ad189m02(暂无昵称), createdTime=Fri Mar 08 09:34:46 CST 2024, time=2024-03-08, status=1, ipAttribution=北京)]
    2025-05-02 ms6000001390648073

    审稿速度:1.0
    偏重的研究方向：肿瘤;标志物
    经验分享：with editor两周peer review

    2

    展开2条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2127118, encodeId=dd57212e11861, content=生信+实验收吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=261c5473647, createdName=ms1000000858912769, createdTime=Wed Apr 19 20:46:55 CST 2023, time=2023-04-19, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2263172, encodeId=b33722631e26f, content=审稿速度:1.0<br>偏重的研究方向：肿瘤;标志物<br>经验分享：with editor两周peer review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05805608050, createdName=ms6000001390648073, createdTime=Fri May 02 14:25:31 CST 2025, time=2025-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2241152, encodeId=4c612241152c6, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤;遗传<br>经验分享：投稿10天了，在With editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18286518503, createdName=ms4000000726733331, createdTime=Fri Dec 06 22:45:15 CST 2024, time=2024-12-06, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2253089, encodeId=be662253089a4, content=投稿命中率:95.0<br>经验分享：垃圾杂志，投了半个月还在with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80862476544, createdName=1244bb2bm58(暂无昵称), createdTime=Sat Feb 22 14:14:37 CST 2025, time=2025-02-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2259792, encodeId=773b2259e9254, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：肿瘤<br>经验分享：难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51945464829, createdName=ms1000001718056820, createdTime=Wed Apr 09 20:17:18 CST 2025, time=2025-04-09, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2252640, encodeId=76eb225264051, content=偏重的研究方向：分子生物学;肿瘤<br>经验分享：综述。最开始投的是Journal of Hematology & Oncology，然后推荐转投。下面是时间表，供大家参考。 Submission received-04 Nov 2024 Ready for editorial assignment-05 Nov 2024 Editor assigned-05 Nov 2024 First reviewer(s) invited-18 Nov 2024 Revision requested-16 Dec 2024 Revision received-25 Jan 2025 Revision requested-02 Feb 2025 Submission accepted-11 Feb 2025, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24889227969, createdName=ms4000000145088894, createdTime=Wed Feb 19 14:17:01 CST 2025, time=2025-02-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2252639, encodeId=853a225263940, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：分子生物学;肿瘤<br>经验分享：综述。最开始投的是Journal of Hematology & Oncology，然后推荐转投。下面是时间表，供大家参考。<br>Submission received-04 Nov 2024<br>Ready for editorial assignment-05 Nov 2024<br>Editor assigned-05 Nov 2024<br>First reviewer(s) invited-18 Nov 2024<br>Revision requested-16 Dec 2024<br>Revision received-25 Jan 2025<br>Revision requested-02 Feb 2025<br>Submission accepted-11 Feb 2025<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24889227969, createdName=ms4000000145088894, createdTime=Wed Feb 19 14:09:36 CST 2025, time=2025-02-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2245674, encodeId=83f622456e45e, content=还没投，来看看大家的意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=9cc95195872, createdName=14728102m68暂无昵称, createdTime=Tue Dec 31 09:09:15 CST 2024, time=2024-12-31, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2238194, encodeId=2fbb223819434, content=审稿速度:12.0 | 投稿命中率:5.0<br>经验分享：lj杂志，两个审稿人都同意接收的前提下编辑没有任何理由给拒了，半年白费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66255430118, createdName=ms2000001500604715, createdTime=Thu Nov 21 16:15:16 CST 2024, time=2024-11-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2191999, encodeId=591c2191999ef, content=The editors' decision can take several weeks as they may consult peer reviewers. 是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=780c5321661, createdName=148ad189m02(暂无昵称), createdTime=Fri Mar 08 09:34:46 CST 2024, time=2024-03-08, status=1, ipAttribution=北京)]
    2024-12-06 ms4000000726733331 来自海南省

    审稿速度:1.0 | 投稿命中率:50.0
    偏重的研究方向：肿瘤;遗传
    经验分享：投稿10天了，在With editor

    4

    展开4条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2127118, encodeId=dd57212e11861, content=生信+实验收吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=261c5473647, createdName=ms1000000858912769, createdTime=Wed Apr 19 20:46:55 CST 2023, time=2023-04-19, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2263172, encodeId=b33722631e26f, content=审稿速度:1.0<br>偏重的研究方向：肿瘤;标志物<br>经验分享：with editor两周peer review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05805608050, createdName=ms6000001390648073, createdTime=Fri May 02 14:25:31 CST 2025, time=2025-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2241152, encodeId=4c612241152c6, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤;遗传<br>经验分享：投稿10天了，在With editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18286518503, createdName=ms4000000726733331, createdTime=Fri Dec 06 22:45:15 CST 2024, time=2024-12-06, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2253089, encodeId=be662253089a4, content=投稿命中率:95.0<br>经验分享：垃圾杂志，投了半个月还在with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80862476544, createdName=1244bb2bm58(暂无昵称), createdTime=Sat Feb 22 14:14:37 CST 2025, time=2025-02-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2259792, encodeId=773b2259e9254, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：肿瘤<br>经验分享：难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51945464829, createdName=ms1000001718056820, createdTime=Wed Apr 09 20:17:18 CST 2025, time=2025-04-09, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2252640, encodeId=76eb225264051, content=偏重的研究方向：分子生物学;肿瘤<br>经验分享：综述。最开始投的是Journal of Hematology & Oncology，然后推荐转投。下面是时间表，供大家参考。 Submission received-04 Nov 2024 Ready for editorial assignment-05 Nov 2024 Editor assigned-05 Nov 2024 First reviewer(s) invited-18 Nov 2024 Revision requested-16 Dec 2024 Revision received-25 Jan 2025 Revision requested-02 Feb 2025 Submission accepted-11 Feb 2025, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24889227969, createdName=ms4000000145088894, createdTime=Wed Feb 19 14:17:01 CST 2025, time=2025-02-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2252639, encodeId=853a225263940, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：分子生物学;肿瘤<br>经验分享：综述。最开始投的是Journal of Hematology & Oncology，然后推荐转投。下面是时间表，供大家参考。<br>Submission received-04 Nov 2024<br>Ready for editorial assignment-05 Nov 2024<br>Editor assigned-05 Nov 2024<br>First reviewer(s) invited-18 Nov 2024<br>Revision requested-16 Dec 2024<br>Revision received-25 Jan 2025<br>Revision requested-02 Feb 2025<br>Submission accepted-11 Feb 2025<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24889227969, createdName=ms4000000145088894, createdTime=Wed Feb 19 14:09:36 CST 2025, time=2025-02-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2245674, encodeId=83f622456e45e, content=还没投，来看看大家的意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=9cc95195872, createdName=14728102m68暂无昵称, createdTime=Tue Dec 31 09:09:15 CST 2024, time=2024-12-31, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2238194, encodeId=2fbb223819434, content=审稿速度:12.0 | 投稿命中率:5.0<br>经验分享：lj杂志，两个审稿人都同意接收的前提下编辑没有任何理由给拒了，半年白费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66255430118, createdName=ms2000001500604715, createdTime=Thu Nov 21 16:15:16 CST 2024, time=2024-11-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2191999, encodeId=591c2191999ef, content=The editors' decision can take several weeks as they may consult peer reviewers. 是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=780c5321661, createdName=148ad189m02(暂无昵称), createdTime=Fri Mar 08 09:34:46 CST 2024, time=2024-03-08, status=1, ipAttribution=北京)]
    2025-02-22 1244bb2bm58(暂无昵称) 来自广东省

    投稿命中率:95.0
    经验分享：垃圾杂志，投了半个月还在with editor

    4

    展开4条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2127118, encodeId=dd57212e11861, content=生信+实验收吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=261c5473647, createdName=ms1000000858912769, createdTime=Wed Apr 19 20:46:55 CST 2023, time=2023-04-19, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2263172, encodeId=b33722631e26f, content=审稿速度:1.0<br>偏重的研究方向：肿瘤;标志物<br>经验分享：with editor两周peer review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05805608050, createdName=ms6000001390648073, createdTime=Fri May 02 14:25:31 CST 2025, time=2025-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2241152, encodeId=4c612241152c6, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤;遗传<br>经验分享：投稿10天了，在With editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18286518503, createdName=ms4000000726733331, createdTime=Fri Dec 06 22:45:15 CST 2024, time=2024-12-06, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2253089, encodeId=be662253089a4, content=投稿命中率:95.0<br>经验分享：垃圾杂志，投了半个月还在with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80862476544, createdName=1244bb2bm58(暂无昵称), createdTime=Sat Feb 22 14:14:37 CST 2025, time=2025-02-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2259792, encodeId=773b2259e9254, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：肿瘤<br>经验分享：难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51945464829, createdName=ms1000001718056820, createdTime=Wed Apr 09 20:17:18 CST 2025, time=2025-04-09, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2252640, encodeId=76eb225264051, content=偏重的研究方向：分子生物学;肿瘤<br>经验分享：综述。最开始投的是Journal of Hematology & Oncology，然后推荐转投。下面是时间表，供大家参考。 Submission received-04 Nov 2024 Ready for editorial assignment-05 Nov 2024 Editor assigned-05 Nov 2024 First reviewer(s) invited-18 Nov 2024 Revision requested-16 Dec 2024 Revision received-25 Jan 2025 Revision requested-02 Feb 2025 Submission accepted-11 Feb 2025, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24889227969, createdName=ms4000000145088894, createdTime=Wed Feb 19 14:17:01 CST 2025, time=2025-02-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2252639, encodeId=853a225263940, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：分子生物学;肿瘤<br>经验分享：综述。最开始投的是Journal of Hematology & Oncology，然后推荐转投。下面是时间表，供大家参考。<br>Submission received-04 Nov 2024<br>Ready for editorial assignment-05 Nov 2024<br>Editor assigned-05 Nov 2024<br>First reviewer(s) invited-18 Nov 2024<br>Revision requested-16 Dec 2024<br>Revision received-25 Jan 2025<br>Revision requested-02 Feb 2025<br>Submission accepted-11 Feb 2025<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24889227969, createdName=ms4000000145088894, createdTime=Wed Feb 19 14:09:36 CST 2025, time=2025-02-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2245674, encodeId=83f622456e45e, content=还没投，来看看大家的意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=9cc95195872, createdName=14728102m68暂无昵称, createdTime=Tue Dec 31 09:09:15 CST 2024, time=2024-12-31, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2238194, encodeId=2fbb223819434, content=审稿速度:12.0 | 投稿命中率:5.0<br>经验分享：lj杂志，两个审稿人都同意接收的前提下编辑没有任何理由给拒了，半年白费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66255430118, createdName=ms2000001500604715, createdTime=Thu Nov 21 16:15:16 CST 2024, time=2024-11-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2191999, encodeId=591c2191999ef, content=The editors' decision can take several weeks as they may consult peer reviewers. 是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=780c5321661, createdName=148ad189m02(暂无昵称), createdTime=Fri Mar 08 09:34:46 CST 2024, time=2024-03-08, status=1, ipAttribution=北京)]
    2025-04-09 ms1000001718056820 来自广东省

    审稿速度:2.0 | 投稿命中率:75.0
    偏重的研究方向：肿瘤
    经验分享：难

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2127118, encodeId=dd57212e11861, content=生信+实验收吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=261c5473647, createdName=ms1000000858912769, createdTime=Wed Apr 19 20:46:55 CST 2023, time=2023-04-19, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2263172, encodeId=b33722631e26f, content=审稿速度:1.0<br>偏重的研究方向：肿瘤;标志物<br>经验分享：with editor两周peer review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05805608050, createdName=ms6000001390648073, createdTime=Fri May 02 14:25:31 CST 2025, time=2025-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2241152, encodeId=4c612241152c6, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤;遗传<br>经验分享：投稿10天了，在With editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18286518503, createdName=ms4000000726733331, createdTime=Fri Dec 06 22:45:15 CST 2024, time=2024-12-06, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2253089, encodeId=be662253089a4, content=投稿命中率:95.0<br>经验分享：垃圾杂志，投了半个月还在with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80862476544, createdName=1244bb2bm58(暂无昵称), createdTime=Sat Feb 22 14:14:37 CST 2025, time=2025-02-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2259792, encodeId=773b2259e9254, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：肿瘤<br>经验分享：难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51945464829, createdName=ms1000001718056820, createdTime=Wed Apr 09 20:17:18 CST 2025, time=2025-04-09, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2252640, encodeId=76eb225264051, content=偏重的研究方向：分子生物学;肿瘤<br>经验分享：综述。最开始投的是Journal of Hematology & Oncology，然后推荐转投。下面是时间表，供大家参考。 Submission received-04 Nov 2024 Ready for editorial assignment-05 Nov 2024 Editor assigned-05 Nov 2024 First reviewer(s) invited-18 Nov 2024 Revision requested-16 Dec 2024 Revision received-25 Jan 2025 Revision requested-02 Feb 2025 Submission accepted-11 Feb 2025, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24889227969, createdName=ms4000000145088894, createdTime=Wed Feb 19 14:17:01 CST 2025, time=2025-02-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2252639, encodeId=853a225263940, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：分子生物学;肿瘤<br>经验分享：综述。最开始投的是Journal of Hematology & Oncology，然后推荐转投。下面是时间表，供大家参考。<br>Submission received-04 Nov 2024<br>Ready for editorial assignment-05 Nov 2024<br>Editor assigned-05 Nov 2024<br>First reviewer(s) invited-18 Nov 2024<br>Revision requested-16 Dec 2024<br>Revision received-25 Jan 2025<br>Revision requested-02 Feb 2025<br>Submission accepted-11 Feb 2025<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24889227969, createdName=ms4000000145088894, createdTime=Wed Feb 19 14:09:36 CST 2025, time=2025-02-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2245674, encodeId=83f622456e45e, content=还没投，来看看大家的意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=9cc95195872, createdName=14728102m68暂无昵称, createdTime=Tue Dec 31 09:09:15 CST 2024, time=2024-12-31, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2238194, encodeId=2fbb223819434, content=审稿速度:12.0 | 投稿命中率:5.0<br>经验分享：lj杂志，两个审稿人都同意接收的前提下编辑没有任何理由给拒了，半年白费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66255430118, createdName=ms2000001500604715, createdTime=Thu Nov 21 16:15:16 CST 2024, time=2024-11-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2191999, encodeId=591c2191999ef, content=The editors' decision can take several weeks as they may consult peer reviewers. 是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=780c5321661, createdName=148ad189m02(暂无昵称), createdTime=Fri Mar 08 09:34:46 CST 2024, time=2024-03-08, status=1, ipAttribution=北京)]
    2025-02-19 ms4000000145088894 来自浙江省

    偏重的研究方向：分子生物学;肿瘤
    经验分享：综述。最开始投的是Journal of Hematology & Oncology，然后推荐转投。下面是时间表，供大家参考。 Submission received-04 Nov 2024 Ready for editorial assignment-05 Nov 2024 Editor assigned-05 Nov 2024 First reviewer(s) invited-18 Nov 2024 Revision requested-16 Dec 2024 Revision received-25 Jan 2025 Revision requested-02 Feb 2025 Submission accepted-11 Feb 2025

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2127118, encodeId=dd57212e11861, content=生信+实验收吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=261c5473647, createdName=ms1000000858912769, createdTime=Wed Apr 19 20:46:55 CST 2023, time=2023-04-19, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2263172, encodeId=b33722631e26f, content=审稿速度:1.0<br>偏重的研究方向：肿瘤;标志物<br>经验分享：with editor两周peer review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05805608050, createdName=ms6000001390648073, createdTime=Fri May 02 14:25:31 CST 2025, time=2025-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2241152, encodeId=4c612241152c6, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤;遗传<br>经验分享：投稿10天了，在With editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18286518503, createdName=ms4000000726733331, createdTime=Fri Dec 06 22:45:15 CST 2024, time=2024-12-06, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2253089, encodeId=be662253089a4, content=投稿命中率:95.0<br>经验分享：垃圾杂志，投了半个月还在with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80862476544, createdName=1244bb2bm58(暂无昵称), createdTime=Sat Feb 22 14:14:37 CST 2025, time=2025-02-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2259792, encodeId=773b2259e9254, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：肿瘤<br>经验分享：难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51945464829, createdName=ms1000001718056820, createdTime=Wed Apr 09 20:17:18 CST 2025, time=2025-04-09, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2252640, encodeId=76eb225264051, content=偏重的研究方向：分子生物学;肿瘤<br>经验分享：综述。最开始投的是Journal of Hematology & Oncology，然后推荐转投。下面是时间表，供大家参考。 Submission received-04 Nov 2024 Ready for editorial assignment-05 Nov 2024 Editor assigned-05 Nov 2024 First reviewer(s) invited-18 Nov 2024 Revision requested-16 Dec 2024 Revision received-25 Jan 2025 Revision requested-02 Feb 2025 Submission accepted-11 Feb 2025, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24889227969, createdName=ms4000000145088894, createdTime=Wed Feb 19 14:17:01 CST 2025, time=2025-02-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2252639, encodeId=853a225263940, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：分子生物学;肿瘤<br>经验分享：综述。最开始投的是Journal of Hematology & Oncology，然后推荐转投。下面是时间表，供大家参考。<br>Submission received-04 Nov 2024<br>Ready for editorial assignment-05 Nov 2024<br>Editor assigned-05 Nov 2024<br>First reviewer(s) invited-18 Nov 2024<br>Revision requested-16 Dec 2024<br>Revision received-25 Jan 2025<br>Revision requested-02 Feb 2025<br>Submission accepted-11 Feb 2025<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24889227969, createdName=ms4000000145088894, createdTime=Wed Feb 19 14:09:36 CST 2025, time=2025-02-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2245674, encodeId=83f622456e45e, content=还没投，来看看大家的意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=9cc95195872, createdName=14728102m68暂无昵称, createdTime=Tue Dec 31 09:09:15 CST 2024, time=2024-12-31, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2238194, encodeId=2fbb223819434, content=审稿速度:12.0 | 投稿命中率:5.0<br>经验分享：lj杂志，两个审稿人都同意接收的前提下编辑没有任何理由给拒了，半年白费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66255430118, createdName=ms2000001500604715, createdTime=Thu Nov 21 16:15:16 CST 2024, time=2024-11-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2191999, encodeId=591c2191999ef, content=The editors' decision can take several weeks as they may consult peer reviewers. 是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=780c5321661, createdName=148ad189m02(暂无昵称), createdTime=Fri Mar 08 09:34:46 CST 2024, time=2024-03-08, status=1, ipAttribution=北京)]
    2025-02-19 ms4000000145088894 来自浙江省

    审稿速度:3.0 | 投稿命中率:50.0
    偏重的研究方向：分子生物学;肿瘤
    经验分享：综述。最开始投的是Journal of Hematology & Oncology，然后推荐转投。下面是时间表，供大家参考。
    Submission received-04 Nov 2024
    Ready for editorial assignment-05 Nov 2024
    Editor assigned-05 Nov 2024
    First reviewer(s) invited-18 Nov 2024
    Revision requested-16 Dec 2024
    Revision received-25 Jan 2025
    Revision requested-02 Feb 2025
    Submission accepted-11 Feb 2025





























    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2127118, encodeId=dd57212e11861, content=生信+实验收吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=261c5473647, createdName=ms1000000858912769, createdTime=Wed Apr 19 20:46:55 CST 2023, time=2023-04-19, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2263172, encodeId=b33722631e26f, content=审稿速度:1.0<br>偏重的研究方向：肿瘤;标志物<br>经验分享：with editor两周peer review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05805608050, createdName=ms6000001390648073, createdTime=Fri May 02 14:25:31 CST 2025, time=2025-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2241152, encodeId=4c612241152c6, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤;遗传<br>经验分享：投稿10天了，在With editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18286518503, createdName=ms4000000726733331, createdTime=Fri Dec 06 22:45:15 CST 2024, time=2024-12-06, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2253089, encodeId=be662253089a4, content=投稿命中率:95.0<br>经验分享：垃圾杂志，投了半个月还在with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80862476544, createdName=1244bb2bm58(暂无昵称), createdTime=Sat Feb 22 14:14:37 CST 2025, time=2025-02-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2259792, encodeId=773b2259e9254, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：肿瘤<br>经验分享：难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51945464829, createdName=ms1000001718056820, createdTime=Wed Apr 09 20:17:18 CST 2025, time=2025-04-09, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2252640, encodeId=76eb225264051, content=偏重的研究方向：分子生物学;肿瘤<br>经验分享：综述。最开始投的是Journal of Hematology & Oncology，然后推荐转投。下面是时间表，供大家参考。 Submission received-04 Nov 2024 Ready for editorial assignment-05 Nov 2024 Editor assigned-05 Nov 2024 First reviewer(s) invited-18 Nov 2024 Revision requested-16 Dec 2024 Revision received-25 Jan 2025 Revision requested-02 Feb 2025 Submission accepted-11 Feb 2025, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24889227969, createdName=ms4000000145088894, createdTime=Wed Feb 19 14:17:01 CST 2025, time=2025-02-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2252639, encodeId=853a225263940, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：分子生物学;肿瘤<br>经验分享：综述。最开始投的是Journal of Hematology & Oncology，然后推荐转投。下面是时间表，供大家参考。<br>Submission received-04 Nov 2024<br>Ready for editorial assignment-05 Nov 2024<br>Editor assigned-05 Nov 2024<br>First reviewer(s) invited-18 Nov 2024<br>Revision requested-16 Dec 2024<br>Revision received-25 Jan 2025<br>Revision requested-02 Feb 2025<br>Submission accepted-11 Feb 2025<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24889227969, createdName=ms4000000145088894, createdTime=Wed Feb 19 14:09:36 CST 2025, time=2025-02-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2245674, encodeId=83f622456e45e, content=还没投，来看看大家的意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=9cc95195872, createdName=14728102m68暂无昵称, createdTime=Tue Dec 31 09:09:15 CST 2024, time=2024-12-31, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2238194, encodeId=2fbb223819434, content=审稿速度:12.0 | 投稿命中率:5.0<br>经验分享：lj杂志，两个审稿人都同意接收的前提下编辑没有任何理由给拒了，半年白费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66255430118, createdName=ms2000001500604715, createdTime=Thu Nov 21 16:15:16 CST 2024, time=2024-11-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2191999, encodeId=591c2191999ef, content=The editors' decision can take several weeks as they may consult peer reviewers. 是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=780c5321661, createdName=148ad189m02(暂无昵称), createdTime=Fri Mar 08 09:34:46 CST 2024, time=2024-03-08, status=1, ipAttribution=北京)]
    2024-12-31 14728102m68暂无昵称 来自广东省

    还没投，来看看大家的意见

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2127118, encodeId=dd57212e11861, content=生信+实验收吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=261c5473647, createdName=ms1000000858912769, createdTime=Wed Apr 19 20:46:55 CST 2023, time=2023-04-19, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2263172, encodeId=b33722631e26f, content=审稿速度:1.0<br>偏重的研究方向：肿瘤;标志物<br>经验分享：with editor两周peer review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05805608050, createdName=ms6000001390648073, createdTime=Fri May 02 14:25:31 CST 2025, time=2025-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2241152, encodeId=4c612241152c6, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤;遗传<br>经验分享：投稿10天了，在With editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18286518503, createdName=ms4000000726733331, createdTime=Fri Dec 06 22:45:15 CST 2024, time=2024-12-06, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2253089, encodeId=be662253089a4, content=投稿命中率:95.0<br>经验分享：垃圾杂志，投了半个月还在with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80862476544, createdName=1244bb2bm58(暂无昵称), createdTime=Sat Feb 22 14:14:37 CST 2025, time=2025-02-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2259792, encodeId=773b2259e9254, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：肿瘤<br>经验分享：难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51945464829, createdName=ms1000001718056820, createdTime=Wed Apr 09 20:17:18 CST 2025, time=2025-04-09, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2252640, encodeId=76eb225264051, content=偏重的研究方向：分子生物学;肿瘤<br>经验分享：综述。最开始投的是Journal of Hematology & Oncology，然后推荐转投。下面是时间表，供大家参考。 Submission received-04 Nov 2024 Ready for editorial assignment-05 Nov 2024 Editor assigned-05 Nov 2024 First reviewer(s) invited-18 Nov 2024 Revision requested-16 Dec 2024 Revision received-25 Jan 2025 Revision requested-02 Feb 2025 Submission accepted-11 Feb 2025, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24889227969, createdName=ms4000000145088894, createdTime=Wed Feb 19 14:17:01 CST 2025, time=2025-02-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2252639, encodeId=853a225263940, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：分子生物学;肿瘤<br>经验分享：综述。最开始投的是Journal of Hematology & Oncology，然后推荐转投。下面是时间表，供大家参考。<br>Submission received-04 Nov 2024<br>Ready for editorial assignment-05 Nov 2024<br>Editor assigned-05 Nov 2024<br>First reviewer(s) invited-18 Nov 2024<br>Revision requested-16 Dec 2024<br>Revision received-25 Jan 2025<br>Revision requested-02 Feb 2025<br>Submission accepted-11 Feb 2025<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24889227969, createdName=ms4000000145088894, createdTime=Wed Feb 19 14:09:36 CST 2025, time=2025-02-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2245674, encodeId=83f622456e45e, content=还没投，来看看大家的意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=9cc95195872, createdName=14728102m68暂无昵称, createdTime=Tue Dec 31 09:09:15 CST 2024, time=2024-12-31, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2238194, encodeId=2fbb223819434, content=审稿速度:12.0 | 投稿命中率:5.0<br>经验分享：lj杂志，两个审稿人都同意接收的前提下编辑没有任何理由给拒了，半年白费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66255430118, createdName=ms2000001500604715, createdTime=Thu Nov 21 16:15:16 CST 2024, time=2024-11-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2191999, encodeId=591c2191999ef, content=The editors' decision can take several weeks as they may consult peer reviewers. 是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=780c5321661, createdName=148ad189m02(暂无昵称), createdTime=Fri Mar 08 09:34:46 CST 2024, time=2024-03-08, status=1, ipAttribution=北京)]
    2024-11-21 ms2000001500604715 来自上海

    审稿速度:12.0 | 投稿命中率:5.0
    经验分享：lj杂志，两个审稿人都同意接收的前提下编辑没有任何理由给拒了，半年白费

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2127118, encodeId=dd57212e11861, content=生信+实验收吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=261c5473647, createdName=ms1000000858912769, createdTime=Wed Apr 19 20:46:55 CST 2023, time=2023-04-19, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2263172, encodeId=b33722631e26f, content=审稿速度:1.0<br>偏重的研究方向：肿瘤;标志物<br>经验分享：with editor两周peer review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05805608050, createdName=ms6000001390648073, createdTime=Fri May 02 14:25:31 CST 2025, time=2025-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2241152, encodeId=4c612241152c6, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤;遗传<br>经验分享：投稿10天了，在With editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18286518503, createdName=ms4000000726733331, createdTime=Fri Dec 06 22:45:15 CST 2024, time=2024-12-06, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2253089, encodeId=be662253089a4, content=投稿命中率:95.0<br>经验分享：垃圾杂志，投了半个月还在with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80862476544, createdName=1244bb2bm58(暂无昵称), createdTime=Sat Feb 22 14:14:37 CST 2025, time=2025-02-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2259792, encodeId=773b2259e9254, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：肿瘤<br>经验分享：难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51945464829, createdName=ms1000001718056820, createdTime=Wed Apr 09 20:17:18 CST 2025, time=2025-04-09, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2252640, encodeId=76eb225264051, content=偏重的研究方向：分子生物学;肿瘤<br>经验分享：综述。最开始投的是Journal of Hematology & Oncology，然后推荐转投。下面是时间表，供大家参考。 Submission received-04 Nov 2024 Ready for editorial assignment-05 Nov 2024 Editor assigned-05 Nov 2024 First reviewer(s) invited-18 Nov 2024 Revision requested-16 Dec 2024 Revision received-25 Jan 2025 Revision requested-02 Feb 2025 Submission accepted-11 Feb 2025, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24889227969, createdName=ms4000000145088894, createdTime=Wed Feb 19 14:17:01 CST 2025, time=2025-02-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2252639, encodeId=853a225263940, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：分子生物学;肿瘤<br>经验分享：综述。最开始投的是Journal of Hematology & Oncology，然后推荐转投。下面是时间表，供大家参考。<br>Submission received-04 Nov 2024<br>Ready for editorial assignment-05 Nov 2024<br>Editor assigned-05 Nov 2024<br>First reviewer(s) invited-18 Nov 2024<br>Revision requested-16 Dec 2024<br>Revision received-25 Jan 2025<br>Revision requested-02 Feb 2025<br>Submission accepted-11 Feb 2025<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24889227969, createdName=ms4000000145088894, createdTime=Wed Feb 19 14:09:36 CST 2025, time=2025-02-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2245674, encodeId=83f622456e45e, content=还没投，来看看大家的意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=9cc95195872, createdName=14728102m68暂无昵称, createdTime=Tue Dec 31 09:09:15 CST 2024, time=2024-12-31, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2238194, encodeId=2fbb223819434, content=审稿速度:12.0 | 投稿命中率:5.0<br>经验分享：lj杂志，两个审稿人都同意接收的前提下编辑没有任何理由给拒了，半年白费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66255430118, createdName=ms2000001500604715, createdTime=Thu Nov 21 16:15:16 CST 2024, time=2024-11-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2191999, encodeId=591c2191999ef, content=The editors' decision can take several weeks as they may consult peer reviewers. 是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=780c5321661, createdName=148ad189m02(暂无昵称), createdTime=Fri Mar 08 09:34:46 CST 2024, time=2024-03-08, status=1, ipAttribution=北京)]
    2024-03-08 148ad189m02(暂无昵称) 来自北京

    The editors' decision can take several weeks as they may consult peer reviewers. 是送审了吗

    3

    展开3条回复
共115条页码: 1/12页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分